Forbes Tech As Insurers Drop Obesity Drug Coverage, Access Worsens For Those Most In Need
At least 12% of adults in the U.S. have been prescribed a glucagon‐like peptide‐1 drug for one or multiple indications, but 54% of users report affordability challenges.
At least 12% of adults in the U.S. have been prescribed a glucagon‐like peptide‐1 drug for one or multiple indications, but 54% of users report affordability challenges.